The Clinical Application of Neoantigens in Esophageal Cancer
Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors. EC cells present a high tumor mutation burden and harbor...
Saved in:
Published in | Frontiers in oncology Vol. 11; p. 703517 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
27.07.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors. EC cells present a high tumor mutation burden and harbor abundant tumor antigens, including tumor-associated antigens and tumor-specific antigens. The latter, also referred to as neoantigens, are immunogenic mutated peptides presented by major histocompatibility complex class I molecules. While current genomics and bioinformatics technologies have greatly facilitated the identification of tumor neoantigens, identifying individual neoantigens systematically for successful therapies remains a challenging problem. Owing to the initiation of strong, specific tumor-killing cytotoxic T cell responses, neoantigens are emerging as promising targets to develop personalized treatment and have triggered the development of cancer vaccines, adoptive T cell therapies, and combination therapies. This review aims to give a current understanding of the clinical application of neoantigens in EC and provide direction for future investigation. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology These authors have contributed equally to this work and share first authorship Reviewed by: Enrique J. Arenas, Vall d’Hebron Institute of Oncology (VHIO), Spain; Matthias Bozza, German Cancer Research Center (DKFZ), Germany Edited by: Jian-Guo Zhou, University of Erlangen Nuremberg, Germany |
ISSN: | 2234-943X 2234-943X |
DOI: | 10.3389/fonc.2021.703517 |